Zyla life sciences (EGLT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue
Net product sales

-

-

-

-

-

-

-

-

-

-

-

-

-

6,140

4,711

3,450

2,563

2,119

1,296

607

162

-

-

-

-

-

-

-

-

Related party revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

828

346

490

256

-

-

-

-

Collaboration revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

100

-

-

-

-

-

-

-

-

-

-

-

-

Related party revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

390

352

643

-

-

-

-

-

-

-

-

Revenue

19,066

19,297

22,386

22,034

15,810

-

8,153

-

-

7,803

6,651

6,255

5,427

6,140

4,711

3,450

2,663

19,380

1,686

959

805

828

346

490

256

-

-

-

-

Costs and Expenses
Cost of sales (excluding amortization of product rights)

3,444

3,526

10,394

14,172

12,461

-

1,773

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of product rights

3,497

3,497

3,497

3,497

2,332

-

526

-

-

529

528

522

503

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales (excluding amortization of product rights)

-

-

-

-

-

-

-

-

-

-

-

-

-

1,080

914

784

882

2,621

349

207

94

-

-

-

-

-

-

-

-

Amortization of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

500

502

503

501

490

505

585

378

-

-

-

-

-

-

-

-

General and administrative

7,474

5,495

6,044

7,417

3,365

-

5,556

-

-

6,254

6,849

12,471

8,491

7,868

7,950

8,854

5,998

10,294

5,515

5,804

4,861

4,109

3,827

4,516

3,263

1,872

1,252

1,116

855

Sales and marketing

9,972

8,954

9,316

9,135

5,131

-

7,932

-

-

8,131

8,803

9,340

9,258

8,437

6,973

6,280

6,202

5,154

6,283

3,284

1,568

361

367

212

6

-

-

-

-

Research and development

-

10

3

4

5

-

956

-

-

1,557

2,073

4,594

6,520

6,873

12,070

8,697

6,119

7,298

4,602

4,903

10,251

5,908

6,346

7,361

2,780

3,060

1,057

1,200

963

Restructuring and other charges

284

1,272

0

648

0

-

13,864

-

-

-

2,983

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration payable

4,000

1,288

795

2,700

200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

4,830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

33,501

24,042

30,049

37,573

23,494

-

30,607

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

-

-

17,755

22,485

27,999

26,097

24,758

28,409

25,118

19,702

25,857

17,254

14,783

17,152

10,378

10,540

12,089

6,049

4,932

2,309

2,316

1,818

Loss from operations

-14,435

-4,745

-7,663

-15,539

-7,684

-

-22,454

-

-

-9,952

-15,834

-21,744

-20,670

-18,618

-23,698

-21,668

-17,039

-6,477

-15,568

-13,824

-16,347

-9,550

-10,194

-11,599

-5,793

-4,932

-2,309

-2,316

-1,818

Other (income) expense:
Change in fair value of warrant and derivative liability

-

-

-

-

-

-

3,986

-

-

1,034

1,500

0

12

2

-11

43

610

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-592

773

-

-

-

-

-

-

-

-

-

Interest expense (income), net

-3,808

-3,775

-3,749

-3,636

-2,193

-

-32,891

-

-

-3,708

-4,675

-4,749

-4,534

-3,884

-3,601

-2,315

-2,309

-2,340

-2,380

-2,306

-451

4

5

4

-7,092

-

-3,076

-1,367

-

Other gain, net

-

-

1,122

135

-

-

132

-

-

857

60

14

-181

851

12

-69

3

-

-

2

-

-

-

-

-

-

-

-

-

Loss on foreign currency exchange

4

-

-

-

-

-

-

-

-

-

1

-

-

-2

3

-5

2

5

-2

-188

103

0

46

-47

4

-77

-124

-11

22

Total other expense (income)

-3,804

-1,695

-2,627

-3,501

-2,193

-

-28,773

-

-

11,393

-3,114

-4,735

-4,703

-3,033

-3,597

-2,346

-1,694

-1,032

-1,790

-3,265

-348

1,049

51

-43

-7,088

-4,254

-3,200

-1,378

22

Reorganization items

-

-216

0

603

606

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income after reorganization charges and before provision (benefit) for income taxes

-

-

-

-19,643

-

-

-

-

-

-

-18,948

-26,479

-

-21,651

-27,295

-24,014

-18,733

-

-

-

-

-

-

-

-

-

-

-

-

Loss before provision (benefit) for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,358

-17,089

-16,695

-

-10,143

-11,642

-12,881

-9,186

-5,509

-3,694

-1,796

Provision (benefit) for income taxes

-

-

-

-

-

-

-

-

-

-

0

0

-

-281

-358

-237

-185

-722

1

-23

26

-39

35

16

35

-

-

-

0

Net (loss) income

-18,239

-6,224

-10,290

-19,643

-10,483

-

-51,227

-

-12,355

1,441

-18,948

-26,479

-25,373

-21,370

-26,937

-23,777

-18,548

-6,787

-17,359

-17,066

-16,721

-8,462

-10,178

-11,658

-12,916

-9,208

-5,509

-3,694

-1,796

Per share information:
Net (loss) income per share of common stock—basic and diluted (in dollars per share)

-1.26

-0.43

-0.72

-1.37

-0.73

-

-0.93

-

-

0.47

-0.46

-1.04

-1.02

-0.87

-1.10

-0.97

-0.76

-0.08

-0.81

-1.03

-1.02

-0.27

-0.63

-0.73

-1.34

-7.13

-4.26

-2.86

-1.39

Weighted-average shares outstanding, basic and diluted (in shares)

14,443

14,334

14,333

14,333

14,333

-

55,192

-

-

43,563

41,149

25,542

24,766

24,618

24,565

24,468

24,406

24,463

21,530

16,506

16,451

16,495

16,206

15,887

9,638

1,292

1,292

1,292

1,292

Predecessor
Revenue

-

-

-

-

-

-

-

7,443

6,261

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales (excluding amortization of product rights)

-

-

-

-

-

-

-

1,565

2,216

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of product rights

-

-

-

-

-

-

-

531

537

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

6,694

7,073

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and marketing

-

-

-

-

-

-

-

9,019

9,055

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

999

1,303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

18,808

20,184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-11,365

-13,923

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

-

3,181

5,125

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-3,804

-3,556

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other gain

-

-

-

-

-

-

-

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other expense (income)

-

-

-

-

-

-

-

-598

1,569

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income after reorganization charges and before provision (benefit) for income taxes

-

-

-

-

-

-

-

-11,963

-12,354

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-

-

-

-

-11,963

-12,354

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share of common stock, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-0.22

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

53,302

47,303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-